Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.76 |
| ▸ | CTSL | P07711 | 4/20 | 0.70 |
| ▸ | CTSB | P07858 | 4/20 | 0.70 |
| ▸ | CTSS | P25774 | 3/20 | 0.70 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.64 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.64 |
| ▸ | MME | P08473 | 1/20 | 0.62 |
| ▸ | ECE1 | P42892 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222158 | 1.00 | CTSK (0.76) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL1823902 | 1.00 | CTSK (0.76) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL8583018 | 0.95 | CTSK (0.69) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL20770085 | 0.95 | CTSK (0.77) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL14148467 | 0.95 | CTSK (0.77) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL25406813 | 0.95 | CTSK (0.77) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL4872585 | 0.95 | CTSK (0.77) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL7318823 | 0.95 | CTSK (0.69) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL8823918 | 0.95 | CTSK (0.77) | CTSKCTSLCTSBCTSSCAPN1 | |
| SCHEMBL2930262 | 0.95 | CTSK (0.77) | CTSKCTSLCTSBCTSSCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988538-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2022-04-14 | — | — | US | claimed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| CN-110885358-A | Vaccine for preventing tumor recurrence and metastasis and application method thereof | 浙江爱睦世医学科技有限公司 | 2020-03-17 | — | — | CN | claimed |
| CN-110857315-A | Polypeptide medicine and derivative for treating tumor and use method thereof | 许洋 | 2020-03-03 | — | — | CN | claimed |
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| EP-4733307-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND USING MIXED ANHYDRIDE PROCEDURE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-29 | — | — | EP | disclosed |
| EP-3071702-B1 | SYNTHESIS OF L-NUCLEIC ACIDS BY MEANS OF AN ENZYME | APTARION BIOTECH AG (DE) | 2025-07-16 | — | — | EP | disclosed |
| WO-2025070753-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND USING MIXED ANHYDRIDE PROCEDURE | 中外製薬株式会社 | 2025-04-03 | — | — | WO | disclosed |
| US-20240366779-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | SEAGEN INC (US) | 2024-11-07 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| EP-3988538-B1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG ZHIDA PHARMACEUTICAL CO LTD (CN) | 2024-08-07 | — | — | EP | disclosed |
| WO-1993015041-A1 | ETHANOLAMINE DERIVATIVES HAVING SYMPATHOMIMETIC AND ANTI-POLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-08-05 | — | — | WO | disclosed |
| EP-0077274-B1 | 3-AMINO-2-HYDROXY-4-PHENYLBUTANOIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1985-08-28 | — | — | EP | disclosed |
| US-4474764-A | ANALGESICS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1984-10-02 | — | — | US | disclosed |
| US-4382142-A | ANTITUMOR AND ANTICARCINOGENIC AGENTS; LEUKEMIA | KOWA CO., LTD. (JP) | 1983-05-03 | — | — | US | disclosed |
| EP-0077274-A1 | 3-Amino-2-hydroxy-4-phenylbutanoic acid derivatives and pharmaceutical composition containing the same | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1983-04-20 | — | — | EP | disclosed |
| US-4278595-A | TRIPEPTIDES | VEGA LABORATORIES, INC. (US) | 1981-07-14 | — | — | US | disclosed |
| US-4171412-A | COPOLYMER OF HYDROXYALKYLAMIDE OR HYDROXYALKYL ESTER OF ACRYLIC OR METHACRYLIC ACID AND CROSSLINKING ETHYLENE GLYCOL DIACRYLATE OR DIMETHACRYLATE | CESKOSLOVENSKA AKADEMIE VED (CS) | 1979-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616676-B2 | Preparation method and use of modified hydrophobic excipient | CETP, LIPA, MTTP | CTSK 2251/4885CTSL 1366/4885CTSB 1304/4885 |
| US-20240366779-A1 | SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | CTSB, CTSE, CTSZ | CTSK 11/4885CTSL 14/4885CTSB 1/4885 |
| US-20220111055-A1 | MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF | CETP, SLC43A1, SLC27A1 | CTSK 4188/4885CTSL 1811/4885CTSB 3814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.